JSM Bioavailability and Bioequivalence

An open label, balanced, randomized, two treatments, two sequences, two periods, crossover, single dose, bioequivalence study of lafigin dt (lamotrigine) 200 mg orally dispersible tablets of laboratorios recalcine s.a. Chile and lamictal odt® (lamotrigine) 200 mg orally dispersible tablets of glaxosmithkline llc, in healthy, adult, human subjects under fasting condition

Research Article | Open Access | Volume 2 | Issue 1

  • 1. AZIDUS Laboratories Ltd.
  • 2. Carolina Briceño, Julio Jimenez, Lorena Galeotti. ABBOTT, Chile
+ Show More - Show Less
Corresponding Authors
Srinivas G, AZIDUS Laboratories Ltd, India, Tel: +91-8754578205; E-mail: srinivasgopineedu@azidus.com

Lamotrigine is a phenyltriazine used in the treatment of epilepsy and bipolar disorder type I. The purpose of this study was to evaluate the bioequivalence between Lafigin DT (Lamotrigine) 200 mg orally dispersible Tablets of Laboratorios Recalcine S.A. Chile and LAMICTAL ODT® (Lamotrigine) 200 mg orally dispersible Tablets of Glaxosmithkline LLC in healthy, adult, human subjects. An open label, balanced, randomized, two treatments, two sequences, two periods, crossover, single dose study with washout period of 10 days under fasting condition was carried out in 28 subjects in the age group of 26 to 43 years and 27 subjects completed the study. All the subjects included in the study were males and Asians. The pharmacokinetic samples collected from subjects who completed the study were analysed to determine the plasma concentration of Lamotrigine using a validated bio-analytical method. The 90% confidence interval of Cmax and AUC0-72 were 87.03% - 106.32% and 84.23% - 100.64%, respectively which were within the acceptable limits for Cmax of 80.00 % to 125.00 %.


• Lamotrigine

• Dispersible tablets

• Bioavailability

• Lamictal

• Bioequivalence

• Pharmacokinetics


Srinivas G, Arjun Arumugam O (2022) An open label, balanced, randomized, two treatments, two sequences, two periods, crossover, single dose, bioequivalence study of lafigin dt (lamotrigine) 200 mg orally dispersible tablets of laboratorios recalcine s.a. Chile and lamictal odt® (lamotrigine) 200 mg orally dispersible tablets of glaxosmithkline llc, in healthy, adult, human subjects under fasting condition. JSM Bioequiv Bioavailab 2(1): 1006.


AUC: Area under the concentration versus time curve; AED: Anti-Epileptic Drugs; AUC0-72: Area under the plasma concentration versus time curve from zero to truncated 72 hours; BMI: Body Mass Index; Cmax: Concentration Maximum; CV: Coefficient of Variation; ISCV: Intra-subject Co-efficient of Variation; LCMS/MS: Liquid Chromatography Tandem Mass Spectrometry; mg: Milligram; mL: Millilitre; ng/mL: Nanogram per millilitre; PK: Pharmacokinetic; Tmax: Time taken to reach maximum concentration; IRB: Institutional Review Board.


Many drug patents have recently expired or are scheduled to expire in the near future. In response, many drug manufacturers have expanded their generic drug profile, which requires them to conduct clinical trials that demonstrate that their generic equivalents perform similarly to the innovator drug product Regulations introduced by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) over the last thirty-five years have strengthened measures to ensure the bioequivalence of drug products, which may be simultaneously manufactured by multiple drug makers.

Bioequivalence and bioavailability testing standards have also emerged following recognition that bioequivalence and variations in the bioavailability of drug products can result in therapeutic failure and/or toxicity. Lamotrigine, an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine’s chemical name is 3, 5-diamino-6-(2, 3-dichlorophenyl)-astriazine, its molecular formula is C9 H7 N5 Cl2 , and its molecular weight is 256.09. Lamotrigine is a white to pale cream-colored powder and has a pKa of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C).

This study was designed to evaluate the relative bioavailability of the test product Lafigin DT (Lamotrigine) 200 mg orally dispersible Tablets of Laboratorios Recalcine S.A. Chile and reference product LAMICTAL ODT® (Lamotrigine) 200 mg orally dispersible Tablets of GlaxoSmithKline LLC in healthy, adult, human subjects under fasting condition.


Test product, dose and mode of administration

Lafigin DT (Lamotrigine) 200 mg orally dispersible Tablets, 01 x 200 mg, Oral with 200 mL of water in sitting posture under fasting condition, Batch: 19AT289.

Reference product, dose and mode of administration

LAMICTAL ODT® (Lamotrigine) 200 mg orally dispersible Tablets, 01 x 200 mg, Oral with 200 mL of water in sitting posture under fasting condition, Batch: 1914200033.


The study protocol with annexes was prepared and IRB approval was obtained before initiation of the study. The subjects were screened and enrolled in the study as per the IRB approved protocol. Written informed consent was obtained from each volunteer in screening visit to initiation of screening procedure and for the study prior to enrolment. Individual counselling was then given to the willing volunteers by the Investigator in private and any questions and concerns were addressed prior to obtaining consent. The Principal investigator/sub-investigator/ physician reviewed all the screening results to assess eligibility of each volunteer. Subjects were enrolled in the study based on the inclusion and exclusion criteria.

This study was designed based on the known pharmacokinetic profile of the investigational product and general accepted standards for the conduct of bio-equivalence study.

Twenty-eight subjects who met the eligibility criteria were enrolled and dosed with a single dose of either test or reference product in sitting posture at a fixed time in each period. Washout period of 10 days was maintained between each period, in order to minimize any possibility of carryover effect from preceding treatment. The blood samples were collected at pre-defined time intervals for the measurement of concentration and pharmacokinetic parameters of Lamotrigine in both the periods.(Figure 1-2).

Linear Plot of Mean Plasmatic Lamotrigine Concentration vs. Time Points (N=27).

Figure 1 Linear Plot of Mean Plasmatic Lamotrigine Concentration vs. Time Points (N=27).

Semi log Plot of Mean Plasmatic Lamotrigine Concentration vs. Time Points (N=27).

Figure 2 Semi log Plot of Mean Plasmatic Lamotrigine Concentration vs. Time Points (N=27).

Data obtained from 27 subjects who completed the study were used for the pharmacokinetic statistical analysis of Lamotrigine.

Bioequivalence was determined by statistical comparison of Ln-transformed data of Cmax and AUC0-72 of the test and reference formulations using SAS version 9.4.

Study Criteria for inclusion/exclusion of subjects

Healthy volunteers, aged 18 to 45 years, and with BMI of 18.50 - 29.99 Kg/m2 and weight > 50 Kg were eligible to be enrolled in the study.

Inclusion criteria encompassed no evidence of cardiac, pulmonary, gastrointestinal, hepatic, renal, hematologic, or neurologic disorders, or any acute or chronic disease, no history of drug or alcohol addiction, normal laboratory tests (complete blood counts, urinalysis, liver and kidney function, and blood sugar); and serological negativity HIV, hepatitis B.

Subjects were informed by an investigator about the purposes and risks of the study. They were asked to abstain from using concomitant medications, including over-the-counter products, dietary supplements and natural products which potentially modify kinetics / dynamics of Lamotrigine, 14 days prior to dosing and throughout the end of the study. Consumption of grapefruit and/or its products were not allowed within 10 days prior to the start of the study. Caffeine and/or xanthinecontaining products or alcohol were not allowed 48 hours prior the first administration of the study medications and throughout the blood sampling periods.

Sample size and power

An Intrasubject CV of 16% was considered for estimation of sample size. This was obtained from the earlier studies conducted. A desired power of 90% was opted to have adequate data for evaluation of bioequivalence. Difference between formulation was considered to be 5%. The sample size deemed required is about 18 subjects. However, to account for possible dropouts during study conduct due to adverse events or any other reasons, a sample size of 28 subjects was considered.

Subjects drug administration and blood sampling

After an overnight fasting of 10 hours, subjects were administered with a single oral dose of either test product or reference product with 200 mL of water according to the sequence assigned to each subject in sitting posture in each period.

A single oral dose of either test or reference tablet according to randomization schedule was placed on the subjects’ tongue and was asked to move around the mouth. Subjects were instructed to not chew or swallow the tablet. The tablet rapidly disintegrates inside the mouth. Once the tablet completely disintegrated, subjects were instructed to swallow the same with allotted 200 mL of water.

Compliance to drug administration was assessed by examination of the oral cavity and hands of the subject immediately after dosing.

All the subjects remained in sitting posture for 02 hours after dosing. During this restriction period, the subjects were permitted to walk for reasons such as but not limited to the following: natural exigencies. Subjects were restricted from consumption of water for 01 hour before and 01 hour after dosing in each period and allowed to drink water ad libitum thereafter.(Table 1,2)

Table 1: Statistical Results of Test Product-T versus Reference Product - R for Lamotrigine.
Parameters Antilog Least Square Mean Point Estimate (%) 90% Confidence Interval ISCV (%) Power (%)
Test Product (T) Reference Product (R)
Ln (Cmax ) 2862.3778 2975.5473 96.20 87.03% - 106.32% 21.77 97.70
Ln (AUC0-72) 82402.833 89499.719 92.07 84.23% - 100.64% 19.31 99.18


Table 2: Summarized Demographic Profile of Subjects who Completed the Study (N=27).
Parameter Mean SD Minimum Maximum
Age (years) 35 5 26 43
Height (m) 1.668 0.041 1.580 1.730
Weight (Kg) 67.7 7.1 55.6 79.3
BMI (Kg/m2) 24.31 2.18 19.75 28.84


The pharmacokinetic profile of both test and reference products (in terms of rate and extent of absorption) were evaluated based on measured concentration of drug in the human plasma samples collected during the clinical phase. Blood samples for pharmacokinetic analysis were designed appropriately for characterizing the pharmacokinetic profile for the given treatments at the dose administered.

Blood samples, of 04 mL each one, were collected at 00.00 (Pre-dose), 00.17, 00.33, 00.50, 00.75, 01.00, 01.50, 02.00, 03.00, 04.00, 05.00, 06.00, 08.00, 12.00, 16.00, 24.00, 34.00, 48.00 and 72.00 hours post dose for measurement of pharmacokinetic parameters.

The samples collected were subjected to centrifugation and separated to 02 aliquots which were stored at -70º C. During bio analysis, the samples were thawed and a validated method was used to analyse the samples.(Table 3,4)

Table 3: Summary of Pharmacokinetic Parameters for Lamotrigine of Reference Product -R.
Parameter N

Reference (R)

(Mean ± SD)

Cmax (ng/mL) 27 3016.764 ± 541.323
AUC0-72 (ng.hr/mL) 27 91024.762 ± 17359.061
*Tmax (hr) 27 2.00 (0.50 - 4.00)
*Expressed in terms of median (range)


Table 4: Summary of Pharmacokinetic Parameters for Lamotrigine of Test Product -T.
Parameter N Test (T) (Mean ± SD)
Cmax (ng/mL) 27 2923.998 ± 627.449
AUC0-72 (ng.hr/mL) 27 84476.191 ± 17896.168
*Tmax (hr) 27 1.00 (0.33 - 4.00)
*Expressed in terms of median (range)

Lamotrigine was selectively extracted from human plasma by Liquid-Liquid extraction as per the in house procedure. Separation was achieved by reverse phase chromatography and quantification was done using LC-MS/MS method.

Agilent 1290 Binary Pump with Agilent 6460 Triple Quad LC/ MS detector was used for bio analysis and the validated analysis was performed using Lamotrigine and Lamotrigine 13CD3 as reference standards.


Subjects were monitored for adverse events during both periods of the study and ambulatory sampling visits. Subjects were instructed to inform clinical personnel of any untoward medical symptoms and/or events that arose during the study. Prior to check in of each period, subjects were questioned concerning unusual symptoms that may have occurred after the previous administration of the study drug. The Principal Investigator/sub-investigator/ physician also evaluated the subjects for subsequent dosing.

Subjects’ Safety was assessed via continuous monitoring and scheduled recording of safety measurements throughout the study through clinical examinations, vital signs assessment, 12- lead Electrocardiogram (ECG), Chest X - ray, clinical laboratory parameters (e.g., Haematology, Biochemistry, Urine analysis and Serology test) and monitoring subjects’ well-being, symptoms and signs for adverse events.

Pharmacokinetic and Statistical Analysis

The pharmacokinetic and statistical analysis of Lamotrigine was performed using the concentration data obtained from 27 subjects who completed both the periods of the study. In order to test the two one-sided tests for bioequivalence, ratio analysis,90% confidence intervals for the difference between treatments’ least-square mean was calculated for Ln-transformed Cmax and AUC0-72 of Lamotrigine.

Pharmacokinetic parameters were calculated using noncompartmental model of Phoneix® WinNolin® version 8.1 and statistical analysis was carried out using the SAS® statistical software, version 9.4 of SAS Institute Inc, USA.

The mean, standard deviation, standard error, geometric mean, coefficient of variation, minimum, median, maximum and range were calculated for Cmax, AUC0-72, and Tmax.(Table 5)

Table 5: p -Value for Cmax and AUC of Lamotrigine.
Parameters Cmax AUC0-72 Significance
Sequence effect 0.2259 0.5796 Insignificant for Cmax and AUC0-72
Period effect 0.3400 0.6313
Treatment (Formulation) effect 0.5142 0.1255
Subjects nested within sequence 0.8090 0.0926
P < .10 for Sequence effect and P < .05 for all other effects considered to be significant

Twenty-eight subjects in the age group of 26 to 43 years, who met the study eligibility criteria, participated in the study and twenty-seven subjects completed the study. All the 28 subjects enrolled in the study were males and Asians.

One subject (S06) did not report for period II of the study, hence was withdrawn. The clinical study was conducted over a period of 15 days. Blood sampling was done at pre-defined intervals up to 72.00 hours in both the periods, separated by a washout period of 10 days. The pharmacokinetic plasma samples collected from 27 subjects were analysed to determine concentration of Lamotrigine using a validated bio-analytical method in LCMS/MS.

The pharmacokinetic and statistical analyses of Lamotrigine were performed using the concentration data obtained from 27 subjects who completed both the periods of the study. The 90% confidence interval of Cmax and AUC0-72 were 87.03% - 106.32% and 84.23% - 100.64%, respectively, for Lamotrigine, which were within the acceptable limits of 80.00 % to 125.00 %.


The study was carried out in healthy male subjects. The tolerability of Lamotrigine was already well established. In this study, no adverse events are reported indicating that the drug is safe and tolerable at this dose level in healthy subjects.

As indicated in the package insert of the product, the study was conducted under fasting conditions. Lamotrigine is expected to be less variable and the ISCV reported in the literature indicates the same. Hence, a conventional two way crossover design is opted to evaluate the bioequivalence with optimal number of subjects. The washout period opted did not result in any carryover of the drug to subsequent period. Hence, the washout selected is considered adequate and accurate. The pharmacokinetic parameters estimated in the study are comparable with that of the published data. The sponsor, Abbott had included this study in the dossier submission for the generic drug approval in Chile.


Bioequivalence was demonstrated between Lafigin DT (Lamotrigine) 200 mg orally dispersible Tablets of Laboratorios Recalcine S.A. Chile and LAMICTAL ODT® (Lamotrigine) 200 mg orally dispersible Tablets of Glaxosmithkline LLC, in healthy, adult, human subjects under fasting condition. The 90 % CI of Lafigin DT (Lamotrigine) 200 mg orally dispersible tablets was within the acceptable limits of 80.00 % to 125.00 %. There were no adverse events reported during the study. Thus, it can be considered that both the test and reference products were well tolerated in healthy adult subjects at selected dose level.


1. International Conference on Harmonization (ICH): Harmonized Tripartite Guideline-Guideline for Good Clinical Practice (GCP) - E6 (R2), 2016.

2. CDSCO’s New Drugs and Clinical Trials Rules 2019 G.S.R. 227(E).

3. Structure And Content of Clinical Study Reports E3 Current Step 4 version dated 30 November 1995.

4. 21 Code of Federal Regulations, USFDA.

5. ISP Chile – Technical guide G-BIOF 01 - Guide for performance of Comparative Bioavailability studies in solid pharmaceutical forms of oral administration and systemic action.

6. Formulario F BIOF - 03: presentación De Resultados De Estudio De Biodisponibilidad/Bioequivalencia Para Estableer Equivalencia Terapéutica.

7. Prescribing information of LAMICTAL ODT® (Lamotrigine) 200 mg orally dispersible Tablets of Glaxosmithkline LLC.

8. Sane RT, Francis M, Deo A (1998) Bioequivalence study of lamotrigine tablets in healthy male human volunteers. Indian drugs.1998; 35: 570-573.

9. Srichaiya A, Longchoopol C, Oo-Puthinan S, Sayasathid J, Sripalakit J, Viyoch J, et al. Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, twoperiod, two-sequence crossover study. Clin Ther. 2008; 30: 1844- 1851.

10.Brodie MJ. Lamotrigine. Lancet. 1992: 339: 1397-1400.

11.Ruiz A, Cuesta F, Parra S, Montoya B, Restrepo M, Archbold R, et al. Bioequivalence Evaluation of Two Formulations of Lamotrigine Tablets in Healthy Volunteers. J Bioequiv Availab. 2012: 4: 030-034.

12.Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol. 1997; 12: 10-15.

Arumugam A, Lakshmi G, Srinivas G, Rao N, Chirinos J, et al (2023) Bioequivalence of Two Perampanel 12mg Tablets in Healthy, Adult, Human Subjects under Fed Conditions - An Open Label, Cross Over Study. JSM Bioequiv Bioavailab 3(1): 1009.

Received : 17 Nov 2021
Accepted : 07 Jan 2022
Published : 15 Jan 2022
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X